X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3201) 3201
Book Review (920) 920
Publication (278) 278
Newsletter (152) 152
Newspaper Article (118) 118
Book Chapter (40) 40
Book / eBook (22) 22
Conference Proceeding (15) 15
Trade Publication Article (6) 6
Dissertation (4) 4
Magazine Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2615) 2615
humans (2510) 2510
oncology (1520) 1520
male (1491) 1491
female (1476) 1476
hematology (1458) 1458
middle aged (1396) 1396
lymphomas (1389) 1389
aged (1268) 1268
adult (1193) 1193
cancer (895) 895
chemotherapy (806) 806
lymphoma (786) 786
prognosis (738) 738
non-hodgkins-lymphoma (736) 736
rituximab (687) 687
treatment outcome (663) 663
transplantation (659) 659
care and treatment (607) 607
aged, 80 and over (599) 599
antineoplastic combined chemotherapy protocols - therapeutic use (578) 578
research (468) 468
non-hodgkin's lymphomas (462) 462
mantle cell lymphoma (449) 449
disease-free survival (444) 444
survival analysis (431) 431
survival rate (424) 424
leukemia (420) 420
retrospective studies (419) 419
b-cell lymphoma (413) 413
stem cells (398) 398
survival (378) 378
chronic lymphocytic-leukemia (367) 367
follicular lymphoma (367) 367
adolescent (360) 360
analysis (349) 349
lymphoma, mantle-cell - mortality (345) 345
young adult (330) 330
health aspects (315) 315
medicine & public health (314) 314
therapy (313) 313
immunology (309) 309
risk factors (304) 304
lymphoma, non-hodgkin - mortality (297) 297
neoplasm staging (294) 294
bone-marrow-transplantation (288) 288
antineoplastic agents - therapeutic use (286) 286
diagnosis (278) 278
non-hodgkin lymphoma (261) 261
recurrence (260) 260
hemic and lymphatic diseases (258) 258
hematology, oncology and palliative medicine (257) 257
transplantation, autologous (253) 253
hematopoietic stem cells (232) 232
animals (231) 231
mortality (231) 231
patients (229) 229
follow-up studies (228) 228
lymphoma, non-hodgkin - therapy (228) 228
combined modality therapy (227) 227
lymphoma, mantle-cell - drug therapy (225) 225
antineoplastic combined chemotherapy protocols - administration & dosage (222) 222
progression-free survival (219) 219
lymphoma, non-hodgkin - drug therapy (218) 218
patient outcomes (218) 218
non-hodgkin's lymphoma (213) 213
immunotherapy (208) 208
tumors (207) 207
medical research (206) 206
pathology (205) 205
lymphoma, non-hodgkin - pathology (202) 202
hematopoietic stem cell transplantation (201) 201
antineoplastic combined chemotherapy protocols - adverse effects (195) 195
clinical trials (194) 194
lymphoma, mantle-cell - therapy (194) 194
abridged index medicus (193) 193
article (193) 193
cyclophosphamide (193) 193
expression (193) 193
lymphoma, mantle-cell - pathology (189) 189
cyclophosphamide - administration & dosage (187) 187
disease (184) 184
hematopoietic stem cell transplantation - methods (184) 184
drug therapy (183) 183
high-dose therapy (180) 180
stem-cell transplantation (180) 180
antibodies, monoclonal - therapeutic use (179) 179
phase-ii (179) 179
antibodies, monoclonal, murine-derived (172) 172
apoptosis (172) 172
classification (171) 171
remission induction (171) 171
non-hodgkin-lymphoma (170) 170
bone marrow (169) 169
stem cell transplantation (168) 168
gene expression (167) 167
development and progression (164) 164
immunohistochemistry (163) 163
phase-ii trial (162) 162
transplantation, homologous (153) 153
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3509) 3509
Chinese (8) 8
German (6) 6
Czech (4) 4
Japanese (4) 4
French (3) 3
Portuguese (3) 3
Spanish (3) 3
Polish (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2013, Volume 369, Issue 6, pp. 507 - 516
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2009, Volume 27, Issue 4, pp. 511 - 518
Purpose Mantle cell lymphomas (MCLs) represent a clinically aggressive lymphoma subtype with a poor prognosis. To explore a potential progress in outcome a... 
UNITED-STATES | EUROPEAN-MCL-NETWORK | PROSPECTIVE RANDOMIZED-TRIAL | ONCOLOGY | CYCLOPHOSPHAMIDE | PROGRESSION-FREE SURVIVAL | RITUXIMAB | VINCRISTINE | NON-HODGKINS-LYMPHOMA | CHEMOTHERAPY | TRANSPLANTATION | Lymphoma, Mantle-Cell - mortality | Lymphoma, Mantle-Cell - therapy | Humans | Middle Aged | Aged, 80 and over | Adult | Female | Male | Survival Rate | Aged | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2015, Volume 373, Issue 19, pp. 1835 - 1844
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1250 - 1260
The use of rituximab every 2 months for 3 years after immunochemotherapy and autologous stem-cell transplantation prolonged progression-free and overall... 
TRIAL | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | IMMUNOCHEMOTHERAPY | NORDIC MCL2 | FOLLOW-UP | HIGH-DOSE CYTARABINE | PHASE-3 | INTERGROUP | MCL YOUNGER | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Humans | Middle Aged | Immunologic Factors - administration & dosage | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Lymphoma, Mantle-Cell - drug therapy | Male | Transplantation, Autologous | Combined Modality Therapy | Cytarabine - administration & dosage | Cisplatin - administration & dosage | Lymphoma, Mantle-Cell - mortality | Rituximab - administration & dosage | Lymphoma, Mantle-Cell - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Adult | Female | Aged | Maintenance Chemotherapy | Care and treatment | Usage | Patient outcomes | Mantle cell lymphoma | Stem cells | Outcome and process assessment (Health Care) | Reports | Transplantation | Observations | Medical research | Autografts | Dexamethasone | Cell survival | Hypersensitivity | Stem cell transplantation | Rituximab | Lymphoma | Cancer therapies | Survival | Studies | Chemotherapy | Cytarabine | Platinum | Lymphomas | Index Medicus | Abridged Index Medicus | Life Sciences | Hematology | Human health and pathology
Journal Article
Cancer Research, ISSN 0008-5472, 02/2010, Volume 70, Issue 4, pp. 1408 - 1418
Journal Article
Blood, ISSN 0006-4971, 01/2008, Volume 111, Issue 2, pp. 558 - 565
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2018, Volume 378, Issue 13, pp. 1211 - 1223
Among patients with MCL, many of whom were at high risk, ibrutinib plus venetoclax led to a complete response in 62% at week 16. Among patients with a... 
MEDICINE, GENERAL & INTERNAL | BRUTONS TYROSINE KINASE | WORKING GROUP | PHASE | PROGRESSION-FREE SURVIVAL | RESPONSE ASSESSMENT | CHRONIC LYMPHOCYTIC-LEUKEMIA | NON-HODGKIN-LYMPHOMA | OPEN-LABEL | INHIBITOR | MINIMAL RESIDUAL DISEASE | Lymph Nodes - pathology | Prognosis | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Lymphoma, Mantle-Cell - mortality | Neoplasm, Residual | Bridged Bicyclo Compounds, Heterocyclic - adverse effects | Aged, 80 and over | Female | Historically Controlled Study | Lymphoma, Mantle-Cell - genetics | Pyrazoles - adverse effects | Administration, Oral | Pyrimidines - administration & dosage | Lymphoma, Mantle-Cell - drug therapy | Survival Rate | Bridged Bicyclo Compounds, Heterocyclic - administration & dosage | Bone Marrow Examination | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Pyrazoles - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Agammaglobulinaemia Tyrosine Kinase | Intention to Treat Analysis | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Mutation | Sulfonamides - administration & dosage | Protein-Tyrosine Kinases - antagonists & inhibitors | Treatment outcome | Safety and security measures | Drug therapy | Mantle cell lymphoma | Flow cytometry | p53 Protein | Leukemia | Clinical trials | Cancer therapies | Computed tomography | Vomiting | Bone marrow | Medical research | Risk groups | Hematology | Minimal residual disease | Diarrhea | Fatigue | Nausea | Patients | Lymphoma | Bruton's tyrosine kinase | Polymerase chain reaction | Chemotherapy | Lysis | Response rates | Lymphomas | Positron emission tomography | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2011, Volume 29, Issue 6, pp. 690 - 697
Journal Article
Blood, ISSN 0006-4971, 03/2012, Volume 119, Issue 9, pp. 1963 - 1971
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 6, pp. 520 - 531
This international prospective study showed that maintenance therapy with rituximab was more effective than interferon alfa in prolonging the duration of... 
FCM | MEDICINE, GENERAL & INTERNAL | THERAPY | PROSPECTIVE RANDOMIZED-TRIAL | CYCLOPHOSPHAMIDE | PROGRESSION-FREE SURVIVAL | RITUXIMAB | CHRONIC LYMPHOCYTIC-LEUKEMIA | COMBINATION | FLUDARABINE | STUDY-GROUP GLSG | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Prospective Studies | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Induction Chemotherapy | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Lymphoma, Mantle-Cell - mortality | Aged, 80 and over | Female | Maintenance Chemotherapy | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Survival Rate | Vidarabine - analogs & derivatives | Remission Induction | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Vincristine - therapeutic use | Vincristine - adverse effects | Aged | Vidarabine - administration & dosage | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Prednisone - therapeutic use | Antibodies, Monoclonal, Murine-Derived - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Fludarabine | Mantle cell lymphoma | Aged patients | Dosage and administration | Product/Service Evaluations | Drug therapy | Health aspects | Clinical trials | Prednisone | Lymphoma | Doxorubicin | Patients | Vincristine | α-Interferon | Cyclophosphamide | Motivation | Remission | Lymphomas | Computer centers | Age | Index Medicus | Abridged Index Medicus
Journal Article